Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7305056 | 1.00 | CTSK (0.62) | CTSKCTSS | |
| SCHEMBL9811701 | 0.87 | CTSK (0.47) | CTSKCTSS | |
| SCHEMBL10537984 | 0.85 | CTSK (0.63) | CTSKCTSS | |
| SCHEMBL24863061 | 0.84 | CTSK (0.60) | CTSKCTSS | |
| SCHEMBL345582 | 0.83 | CTSK (0.68) | CTSKCTSS | |
| SCHEMBL3448997 | 0.83 | CTSK (0.68) | CTSKCTSS | |
| SCHEMBL12890827 | 0.83 | CTSK (0.67) | CTSKCTSS | |
| SCHEMBL17614512 | 0.83 | CTSK (0.67) | CTSKCTSS | |
| SCHEMBL1350139 | 0.83 | CTSK (0.68) | CTSKCTSS | |
| SCHEMBL5967151 | 0.81 | CTSK (0.65) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195641-B | Sulfoxonium ylide derivatives as probes for cysteine proteases | 武田药品工业株式会社 | 2024-09-03 | — | — | CN | disclosed |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-0525420-B1 | Pseudopeptides and dipeptides characterised by a substituted methyl ketone moiety at the C-terminus as thiol protease inhibitors | MITSUBISHI CHEM CORP (JP) | 1999-05-12 | — | — | EP | disclosed |
| US-5834508-A | PROTEASE ENZYME INHIBITORS; MUSCLE DISORDERS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0603873-B1 | Aminoketone derivatives | MITSUBISHI CHEM CORP (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5639783-A | POTENT PROTEASE INHIBITOR FOR TREATING MUSCULAR, NERVOUS SYSTEM DISEASES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-06-17 | — | — | US | disclosed |
| US-5424325-A | Inibitors of thiol protease and may be used as therapeutic agents for treating muscular dystrophy, cataracts, strokes | MITSUBISHI KASEI CORPORATION (JP) | 1995-06-13 | — | — | US | disclosed |
| EP-0603873-A1 | Aminoketone derivatives | Mitsubishi Chemical Corporation (JP) | 1994-06-29 | — | — | EP | disclosed |
| EP-0525420-A1 | Pseudopeptides and dipeptides characterised by a substituted methyl ketone moiety at the C-terminus as thiol protease inhibitors | Mitsubishi Chemical Corporation (JP) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | CTSZ, CTSF, CTSL | CTSK 8/4885CTSS 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.